<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04175210</url>
  </required_header>
  <id_info>
    <org_study_id>19-07020533</org_study_id>
    <nct_id>NCT04175210</nct_id>
  </id_info>
  <brief_title>Prospective Randomized Study of Accelerated Radiation Therapy (PRART)</brief_title>
  <acronym>PRART</acronym>
  <official_title>Prospective Randomized Study of Accelerated Radiation Therapy (PRART)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Weill Medical College of Cornell University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with Stage 0 ductal carcinoma in situ (Tis (DCIS), Stage T1-T2, lymph node
      negative(N0) breast cancers will be randomized to receive whole breast radiotherapy with a
      concomitant boost to the tumor bed over 15 fractions (Arm 1, standard) versus 10 fractions
      (Arm 2, experimental).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 21, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with adverse events receiving radiation therapy between the two arms Arm 1 (15 fractions) and Arm 2 (10 fractions).</measure>
    <time_frame>up to 5 years</time_frame>
    <description>rate of grade 3 or higher changes in breast cosmesis on the 10 fraction arm compared to the rate on the 15 fraction arm will be measured.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants who demonstrate local control at 5 year follow up</measure>
    <time_frame>5 years</time_frame>
    <description>assess and compare local control at 5 years between the two arms.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>ARM 1-4050cGY and boost to tumor bed of 4800cGY in 15fractions</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to ARM 1 will receive whole breast radiotherapy of 4050cGY and a concomitant boost to the tumor bed of 4800cGY in 15 fractions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARM 2 - 3200cGY and boost to tumor bed of 4200cGY -10fractions</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to ARM 2 will receive whole breast radiotherapy of 3200cGY and a concomitant boost to the tumor bed of 4200cGY in 10 fractions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation therapy - 3 weeks</intervention_name>
    <description>Patients randomized to ARM 1 will receive whole breast radiotherapy of 4050cGY and a concomitant boost to the tumor bed of 4800cGY in 15 fractions</description>
    <arm_group_label>ARM 1-4050cGY and boost to tumor bed of 4800cGY in 15fractions</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation therapy - 2 weeks</intervention_name>
    <description>Patients randomized to ARM 2 will receive whole breast radiotherapy of 3200cGY and a concomitant boost to the tumor bed of 4200cGY in 10 fractions.</description>
    <arm_group_label>ARM 2 - 3200cGY and boost to tumor bed of 4200cGY -10fractions</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women status post segmental mastectomy

          -  If unilateral, pT1-2 breast cancer excised with negative margins

          -  If bilateral, pT1-2 breast cancer excised with negative margins AND/OR pTis excised
             with negative margins.

          -  Clinically N0 or pN0 or sentinel node negative

          -  Ductal carcinoma in situ DCIS with negative margins (no DCIS on inked margins).

        Exclusion Criteria:

          -  Previous radiation therapy to the ipsilateral breast.

          -  90 days from last surgery, unless s/p adjuvant chemotherapy

          -  60 days from last chemotherapy

          -  Male breast cancer
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Silvia Formenti, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Cornell Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sharanya Chandrasekhar, M.S.</last_name>
    <phone>6469622196</phone>
    <email>shc2043@med.cornell.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pragya Yadav, Ph.D.</last_name>
    <phone>6469622199</phone>
    <email>pry2003@med.cornell.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>New York Presbyterian Hospital at Lower Manhattan Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharanya Chandrasekhar, M.S.</last_name>
      <phone>646-962-2196</phone>
      <email>shc2043@med.cornell.edu</email>
    </contact>
    <contact_backup>
      <last_name>Pragya Yadav, Ph.D.</last_name>
      <phone>6469622199</phone>
      <email>pry2003@med.cornell.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Silvia Formenti, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brooklyn Methodist Hospital - NewYork Presbyterian</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>11215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharanya Chandrasekhar, M.S.</last_name>
      <phone>646-962-2196</phone>
      <email>shc2043@med.cornell.edu</email>
    </contact>
    <contact_backup>
      <last_name>Pragya Yadav, Ph.D.</last_name>
      <phone>6469622199</phone>
      <email>pry2003@med.cornell.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Hani Ashamalla, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York Presbyterian Hospital - Queens</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>11355</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharanya Chandrasekhar, M.S.</last_name>
      <phone>646-962-2196</phone>
      <email>shc2043@med.cornell.edu</email>
    </contact>
    <contact_backup>
      <last_name>Pragya Yadav, Ph.D</last_name>
      <phone>6469622199</phone>
      <email>pry2003@med.cornell.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Steven DiBiase, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>November 20, 2019</study_first_submitted>
  <study_first_submitted_qc>November 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2019</study_first_posted>
  <last_update_submitted>June 5, 2020</last_update_submitted>
  <last_update_submitted_qc>June 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

